Description |
InvivoChem Cat #:V1527CAS #:120685-11-2Purity >=98%Description: Midostaurin (formerly also known as PKC-412, PKC-412A and CGP 41251; trade name: Rydapt), a synthetic indolocarbazole compound, is a multi-targeted kinase inhibitor which inhibits PKCalpha/beta/gamma, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRbeta and VEGFR1/2 with IC50 ranging from 80-500 NM and with potential antiangiogenic and antineoplastic activities. In April 2018, Midostaurin was approved by FDA to treat acute myeloid leukemia. Midostaurin is a synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits PKCalpha, VEGFR2, c-kit, PDGFR and FLT3, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors. References: Pharmacol Ther. 1999 May-Jun; 82(2-3):293-301; Jpn J Pharmacol. 1996 Jan; 70(1):65-72. Related CAS: 179237-49-1 3-Hydroxy Midostaurin (CGP 52421) |
Other info |
Chemical Name: N-((5R, 7R, 8R, 9S)-8-methoxy-9-methyl-16-oxo-6, 7, 8, 9, 15, 16-hexahydro-5H, 14H-17-oxa-4b, 9a, 15-triaza-5, 9-methanodibenzo[b, h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide InChi Key: BMGQWWVMWDBQGC-IIFHNQTCSA-N InChi Code: InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16, 25-26, 32H, 17-18H2, 1-3H3, (H, 36, 40)/t25-, 26-, 32-, 35+/m1/s1 SMILES Code: C[C]12[CH](OC)[CH](N(C(C3=CC=CC=C3)=O)C)C[CH](N4C5=CC=CC=C5C6=C7C(CNC7=O)=C8C9=CC=CC=C9N2C8=C64)O1 |